Reports say a “groundbreaking” new drug used to treat Alzheimer’s is set to be approved by the US Food and Drug Administration following a successful global trial. Drugmaker Eli Lilly said early-stage Alzheimer’s patients who took donanemab had a 40% lower risk of progressing from mild cognitive impairment to mild dementia, or from mild to moderate dementia. The drug also slowed patients’ cognitive decline by 35% compared with those who received a placebo. If approved, donanemab would become the third Alzheimer’s drug available in the US market in recent months – Australia’s Therapeutic Goods Administration (TGA) is currently looking at approving one of those for use here. Experts welcomed the update, but many noted that these drugs aren’t a miracle cure – they slow the progression of the disease.